Carboplatin dosage is calculated by using the estimated glomerular filtration rate (GFR) to achieve a target plasma area under the plasma concentration-time curve (AUC). The aims of the present study were to investigate factors that influence the pharmacokinetics of carboplatin in children with high-risk neuroblastoma, and whether target exposures for carboplatin were achieved using current treatment protocols.
Introduction
Neuroblastoma is the most common solid tumour in childhood that occurs outside of the brain, with an incidence of 25-50 cases per million people [1] . It is an embryonic malignancy, frequently situated either in the adrenal gland or elsewhere along the sympathetic nervous system chain [2] . Patients with neuroblastoma are classified into risk groups (low, intermediate, high and ultra-high) to determine the most appropriate treatment protocol. For children with high-risk neuroblastoma, the tumour has commonly metastasized to other parts of the body. Amplification of the MYCN oncogene, a powerful prognostic marker of rapid tumour progression [3] , identifies patients with localized disease but only up to 30% of high-risk neuroblastoma patients have amplification of this oncogene, with some variation according to age. Treatment with high-dose chemotherapy with autologous bone marrow transplantation has been shown significantly to improve event-free survival for children with high-risk neuroblastoma [4] . High-dose chemotherapy can include treatment with either carboplatin, etoposide and melphalan or busulfan and melphalan [5, 6] .
Carboplatin is a second-generation cisplatin derivative with lower nephrotoxicity, neurotoxicity and gastrointestinal toxicity than cisplatin, enabling it to be used at high doses as part of a myeloablative autologous transplant (MAT) [7] . The drug is largely cleared by the kidneys at a rate comparable to the glomerular filtration rate (GFR) [8, 9] . Following a dose of carboplatin, approximately 60-80% is excreted in the urine within the first 24 h [8, 9] . A clear relationship between carboplatin exposure, as quantified by area under the plasma concentration-time curve (AUC), and toxicity (thrombocytopenia) and response has been observed in ovarian cancer and other tumour types [9] [10] [11] . Therefore, various dosing formulas have been developed to enable dosing to a target AUC using an estimate of GFR [12, 13] .
Renal function is expected to have a significant influence on the pharmacokinetics of carboplatin in children. The aim of the current study was to investigate the key factors that influence the pharmacokinetics of carboplatin in children and to determine whether predefined target exposures for this agent would be achieved using current dosing recommendations. The pharmacokinetics of etoposide and melphalan was also investigated.
Methods

Datasets and study design
The data were obtained from various hospitals and medical centres in the UK (Study 1) and from The Children's Hospital at Westmead (CHW, Sydney, NSW, Australia; Study 2). For Study 1, data were obtained from a European International Society for Paediatric Oncology (SIOP) Neuroblastoma study (SIOPEN, ClinicalTrials.gov #NCT01704716, [5] ). The SIOPEN study [5] was a multicentre, randomized study in children with high-risk neuroblastoma and was designed to investigate whether MAT with busulfan and melphalan resulted in a better 3-year event-free survival than that achieved with carboplatin, etoposide and melphalan (CEM). Written informed consent was obtained from the parents of younger patients (<18 years) and from adult patients (≥18 years of age). The study was approved by local or national ethical committees and review boards in participating countries and by national and international regulatory authorities.
For Study 2 in Australia, the majority of patients were recruited to a series of single-centre research studies that continued from 2006 to 2016 (The Children's Hospital Westmead, Ethics approval numbers: 2006/086, 12SCHN34). More recently, children were recruited to a clinical trial entitled ʻA multicentre study investigating the pharmacokinetics of various chemotherapeutic agents used as conditioning in allogeneic and autologous transplant recipientsʼ (Ethics approval number: HREC/15/SCHN/355). This clinical trial is registered on the Australia New Zealand Clinical Trials Registry (ACTRN12612000544875).
Dosing regimen
The dosing schedules for each of the drugs are described in Table 1 . Carboplatin was administered as continuous intravenous infusions over 4 days (96 h). There were different dosing regimens for each drug, based on GFR criteria (<100 ml min For patients with a GFR <100 ml min -1 1.73 m -2 , carboplatin doses were calculated based on GFR, using either the paediatric Newell formula [12] or the modified Calvert formula [6] (Study 2), to achieve a target AUC of 16.4 mg ml -1 ·min.
For Study 1, GFR was determined using the plasma CL of 51 Cr-EDTA. The paediatric Newell formula [12] 
In Study 2, the CL of 99m Tc-DTPA was used to determine
GFR. An alternate version of the Newell formula [12] was used to calculate carboplatin doses for infants (≤12 kg, Eq. 2):
whereby the uncorrected GFR (ml min -1 ) was used and the target AUC of 16.4 mg ml -1 ·min was used. For the remaining children in Study 2 (> 12 kg and GFR <100 ml min 
where BSA is the body surface area. This modified Calvert formula is similar to the paediatric Newell formula, except BSA is used instead of weight. Patients with a GFR <60 ml min Fully validated assays were used to quantify the concentrations of each drug. For Study 1, carboplatin levels, as free or unbound platinum, were determined in plasma ultrafiltrate using flameless atomic absorption spectrophotometry (AAS), and etoposide concentrations were determined using Liquid chromatography-tandem mass spectrometry using previously described methods [15] . For Study 2, carboplatin was determined using high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection [16] ; etoposide concentrations were determined by HPLC-fluorescence detection [17] ; and melphalan concentrations were determined using an HPLC assay with UV detection [18] . All plasma samples were above the limit of quantification (LOQ; carboplatin, 2 μg ml -1 ; etoposide, 0.5 μg ml -1 ; melphalan, 0.1 μg ml -1 ).
Population pharmacokinetic modelling
There were only two patients who were over the age of 12 years and who were excluded from the dataset [absolute conditional weighted residuals (CWRES) >5]. One was an adult (20 years old), but was excluded for being an outlier when investigating correlations between CL and patient demographics. The other patient (15 years of age) had a missing covariate (GFR), which could not be interpolated because there were no other adolescents in the study. Therefore, the remaining plasma data on children (age range 1.7-8.3 years; n = 53 remaining patients for analysis) were used to develop a population pharmacokinetic model. Population pharmacokinetic analyses were conducted using NONMEM (version 7.3, ICON Development Solutions, Hanover, MD, USA) [19] , with the first-order conditional estimation method with interaction (FOCE-I). Model development was managed using Perl-Speaks-NONMEM 3.5.3 [20] , Pirana 2.8.1 [21] and R (Version 3.2.5) [22] . Model selection was informed by using the objective function value (OFV; À2log likelihood) [23] , whereby a reduction of ≥3.84 points in OFV was considered statistically significant (P < 0.05 with one degree of freedom, approximate asymptotic χ 2 distribution).
One-compartment and two-compartment models were investigated for all three drugs and the actual, timed duration of infusion was used in each case. The base model included an allometric weight model for the CL parameters, WT STD is the median weight of the population. Various statistical models were investigated for each drug. Different residual error models were used for the different study sites to account for any variability between assays.
Covariate modelling and missing covariates
Stepwise covariate modelling and visual inspection of empirical Bayes estimates (EBEs) against the patient characteristics were used to identify significant covariates. A covariate was included in the model if inclusion resulted in a significant decrease in OFV (>3.84 points; P < 0.05) and if the backward elimination of the covariate significantly increased the OFV (>6.63; P < 0.01). These covariates included age, sex, BSA, body mass index, GFR and study site. Both the BSA-normalized GFR (ml min -1 1.73 m -2 ) and actual GFR (ml min -1 ) were investigated as potential covariates. Serum creatinine concentrations were available only for Study 2. A separate analysis was conducted using data from Study 2 to investigate the potential additional effect of serum creatinine levels and creatinine CL (Schwartz equation [24] ) on the CL of CEM component drugs.
Model evaluation
For all three drugs, the respective model was evaluated by visual inspection of goodness-of-fit plots of the observed and predicted concentrations, CWRES and normalized prediction distribution errors (NPDEs). The final model performance was examined by using prediction-corrected visual predictive checks (VPCs) to compare the 5th, 50th and 95th percentiles of the observed concentrations and simulations of concentration-time profiles (1000 replicates) from the final model. A nonparametric bootstrap method (n = 1000) was used to study the uncertainty of all pharmacokinetic parameter estimates in the final model, to obtain the median and 95% confidence interval of the parameter estimates.
Dosing simulations
The final model was used to perform stochastic simulations (n = 100) of concentration-time profiles of carboplatin stratified by GFR (<100 ml min -1 1.73 m -2 and >100 ml min -1
1.73 m -2 ) and weight (≤12 kg and >12 kg). All the patients in the dataset were included and their covariate values were used. Carboplatin dosing protocols (weight-based dosing, modified Calvert formula and paediatric Newell formula) were evaluated to investigate the suitability of these formulas to achieve target AUC (16.4 mg ml -1 ·min ±20%) in children.
The dosing schedule used in the study (Table 1 ) was also to investigate the drug exposure of CEM component drugs in these GFR and weight groups. Statistical analyses were performed using R (Version 3.2.5), using the Mann Whitney U test, whereby a P value of <0.05 was considered statistically significant.
Results
A summary of patient demographics is shown in Table 2 . The median age of the population was 3.5 years, and the oldest patient was 8 years of age. A large range of GFRs was observed, and the median and range of GFR were similar for both studies. There was only one patient with moderate renal impairment (47 ml min -1 1.73 m -2 ), whereas the remaining Table 2 Demographics of subjects in the study. Values are median (range) A total of 51 patients with 1031 observations (carboplatin, n = 300; etoposide, n = 365; melphalan, n = 366) were used for population pharmacokinetic modelling. There were five patients with missing carboplatin dosing information, so the pharmacokinetics of carboplatin was only described in 46 patients. Based on evaluation of the population modelling analysis for each of the three drugs, a two-compartment model provided the best fit for carboplatin, etoposide and melphalan. These models were parameterized in each case in terms of CL, central volume of distribution (V C ), intercompartmental CL (Q) and peripheral volume of distribution (V P ). Interindividual variability could be estimated for CL and V C , but not for the peripheral compartment parameters (Q, V P ). Separate residual error models for each drug were used to account for site-specific variability, which improved the model predictions. Final parameter values for carboplatin, etoposide and melphalan are given in Table 3 .
In children, there is a high correlation between carboplatin CL, GFR (ml min -1 ), body weight and age ( Figure 1 ). Stepwise covariate modelling was implemented and allometric body weight was the most significant covariate. After scaling all pharmacokinetic parameters for body weight, none of the other covariates were significant. Estimating the allometric exponent was also examined, but this did not significantly improve the model fits. GFR was significant for carboplatin at P < 0.05, but it was no longer significant following the backwards elimination step (P < 0.01). In Study 2, serum creatinine concentrations and GFR calculated using the Schwartz formula were not significant covariates for the CL of CEM component drugs. Therefore, the final equations for the CL of CEM were:
where θ CLc , θ CLe and θ CLm are the mean population value of carboplatin CL, etoposide CL and melphalan CL, respectively. All pharmacokinetic parameters were estimated with acceptable precision (<35%), but the residual standard error for carboplatin Q (143%) and V P (69%), and etoposide V P (234%) was high (Table 3) . Eighty-seven per cent of the model runs were successful during the bootstrap procedure. The estimates of eta and epsilon shrinkage were low (<27%). There was good agreement between the observed and predicted concentrations for all three drugs, with no apparent bias in the model predictions (Figure 2, Figure S1 ). As seen with the prediction-corrected VPC (Figure 3) , the variability in the observed concentrations was well captured. The 95% confidence intervals for the model simulations were wide for carboplatin (Figure 3 ), which was due to limited plasma data collected post-infusion with this drug. The correlation between the carboplatin CL predicted by the model and that estimated using both the paediatric Newell formula and the modified Calvert formula was investigated. There was a correlation between the actual carboplatin CL and the estimated carboplatin CL using the Newell formula and the Calvert formula but a large scatter was observed ( Figure S2) . Furthermore, the use of the Newell and Calvert formulas was found to underpredict the actual carboplatin CL for patients with higher CL.
The final model was used to simulate the concentrations of carboplatin, stratified by GFR and weight group (Table 4, Figure 4 ). Various weight-based doses (40-60 mg kg -1 ) were simulated and the dose of 50 mg kg -1 was found to be the best dose to achieve the target AUC. The modified Calvert formula and 50 mg kg -1 dosing performed well in achieving target AUC for children with a GFR <100 ml min for patients with normal renal function to achieve target AUC. However, these doses were too high for this patient group, with a median AUC of 18.5 mg ml -1 ·min and 23.3 mg ml -1 ·min for patients with body weight ≤12 kg and >12 kg, respectively (Table S1 ). By contrast, the use of a weight-based dosing regimen of 50 mg kg -1 would achieve target carboplatin exposures for all GFR groups and weight ranges (Table 4) . Etoposide and melphalan were dosed according to body weight (≤12 kg) and BSA (>12 kg), and the dosing protocols used provided consistent drug exposure across all body weight and GFR groups (Table S1) .
For Study 2, associations between carboplatin AUC and hepatorenal toxicity (renal toxicity and venoocclusive disease), ototoxicity and change in plasma creatinine concentrations were investigated ( Figure S3 ). There was no significant association between exposure to carboplatin, or of the other CEM component drugs, and the incidence of these toxicities, but the patient numbers were small.
Figure 1
Scatterplot matrix of carboplatin clearance (CLN, derived from Newell formula; CLM, derived from modified Calvert formula), glomerular filtration rate (GFR, ml min -1 ), body weight (WGT, kg) and age (years)
Pharmacokinetics of carboplatin
Discussion
The successful use of CEM in MAT requires the attainment of high systemic drug exposures, but is also associated with a high risk of nephrotoxicity [25] , such that achieving desired target 'therapeutic window' exposures is essential. We developed a population pharmacokinetic model for CEM, to investigate the effects of GFR and body size on the pharmacokinetic parameters and to evaluate dosing strategies for the CEM component drugs. For etoposide and melphalan, current weight-based dosing and BSA-based dosing were found to be adequate. There are currently no clinically implemented target AUC values for these two drugs, and dosing basing on body size provides an appropriate standardization of exposure, based on the covariate analysis in the present study. The population estimates of pharmacokinetic parameters for each of the three drugs (Table 3 ) are similar to those reported previously for carboplatin [12] , etoposide [21] and in population analyses of melphalan pharmacokinetics [23, 26] . An influence of renal function on melphalan CL has been previously indicated, but in the current dataset weight was the only parameter that was a significant covariate for CL, and GFR did not explain any further variability. GFR was not identified to be a significant covariate for the CL of CEM component drugs, after adjusting pharmacokinetic parameters for weight. Previous investigations have shown a strong influence of body weight on GFR, across a range of ages and renal functions, in paediatric oncology patients [27] . In the present study, the GFR and body weight of the children were also highly correlated (Figure 1 ). This collinearity between body weight and GFR in children and the lack of additional effect of GFR on CL indicated that body weight alone can explain most of the pharmacokinetic variability observed.
For carboplatin, a weight-based dose of 50 mg kg -1 was found to achieve target exposure (16.4 mg ml -1 ·min) more consistently than the widely used GFR-based methods. The use of a weight-based dosing regimen is also more practical for dosing children and can be applied to those with mild renal impairment and with normal renal function. GFR-based dosing is recommended for achieving target carboplatin exposures. However, there are complex dosing Figure 2 Goodness-of-fit plots for carboplatin, etoposide and melphalan. Observed concentrations were plotted against (A) population predictions and (B) individual predictions with the line of identity (black) and linear regression line (blue). Conditional weighted residuals (CWRES) were against (C) population predictions and (D) time after dose with a locally weighted scatterplot smoothing a (loess) curve (blue). A plot of the distribution of the normalized prediction distribution error (NPDE) (E) and a Q-Q plot of CWRES (F) are shown protocols for children, which vary depending on their weight and GFR. Targeted AUC dosing using the paediatric Newell formula is a widely applied algorithm for carboplatin dosing [12] . This formula was originally derived from a study in 22 children, where the measurement of 51 Cr-EDTA was used to determine the GFR [median 58 (range 14-138) ml min
The suitability of this formula, in terms of providing better attainment of a target AUC, was demonstrated in a randomized, crossover study in 38 patients with a similar range of GFR values (as determined by 51 Cr-EDTA elimination) [28] .
However, in the original study on which the Newell formula was based [12] , the correlation between GFR and carboplatin CL was weaker after accounting for BSA (correlation coefficient R 2 reduction of 0.56 to 0.28), suggesting that variation in body size explains a large proportion of the variability in carboplatin CL in children. Similarly, the modified Calvert formula, which uses the patient's BSA rather than weight, is also widely used to dose carboplatin in children [6, 29] . In a large study of children with retinoblastoma (n = 98), it was found that body weight-based dosing was a reliable alternative method to using the modified Calvert formula [29] .
Based on the current analysis, the use of the paediatric Newell formula resulted in lower carboplatin exposures than the modified Calvert formula, although both formulas were useful in achieving target AUC for children with lower kidney function (<100 ml min -1 1.73 m -2 ; Figure 4 ). As the Newell formula does not require the BSA to be calculated, it is more practical to use the Newell formula over the modified Calvert formula. However, for patients with lower kidney function, there is a risk of underdosing some children when using the Newell formula (Table 4 , Figure 4 ). For children with normal kidney function (≥100 ml min
, the use of these GFR-based dosing formulas would result in significant overdosing of carboplatin, thereby increasing the risk of carboplatin-related toxicities. A significant hurdle to implementing the Newell formula or the modified Calvert formula is the need to obtain an accurate measure of GFR. In children, the estimation of GFR is challenging because none of the available formulas are completely satisfactory, and measures derived from adult populations are only useful for children over 12 years of age [30] . Creatinine CL is an unreliable measure of GFR in children, whereby a mean difference of 41% in paired measurements of 51 Cr-EDTA GFR and creatinine CL was reported [31] . In the present study, GFR was determined based on the CL of radioactive tracers (either 51 Cr-EDTA or 99m Tc-DTPA), which is the most accurate method. There is a potential for dosing errors due to differences in the estimation of GFR between study centres or miscalculation of dosing formulas. Nevertheless, although there are resource and cost implications from using the CL of radioisotopes to measure GFR accurately [14] , use of this method is clearly indicated in high-risk patient populations, such as the neuroblastoma patients studied here.
Other dosing algorithms for carboplatin were explored. The Chatelut formula requires measurements of weight, age and serum creatinine [32] . Serum creatinine concentrations were collected only in Study 2, but this marker of renal function was not a significant covariate for carboplatin CL.
Previous studies have also found GFR to be a significant covariate for melphalan CL. In a previously developed population pharmacokinetic model of melphalan, both body weight and GFR were found to be significant covariates for CL [26] , wherein GFR was determined using 99m Tc-DTPA. As the latter study included a broader age range than that used the Figure 3 Prediction-corrected visual predictive check (VPC) of the final model of (A) carboplatin, (B) etoposide and (C) melphalan. The black lines represent 5th, 50th and 95th percentiles of observed data and the shaded areas represent 95% CI of simulated 5th, 50th and 95% percentiles current study [26] , it is suggested that the differences in the ages between the study groups may have influenced the effect of GFR on melphalan CL. Furthermore, an allometric weight model was not investigated in the previous model [26] , which may have influenced the covariate effect of GFR.
Limitations
The present study was limited to patients with mild renal impairment or normal renal function, as those with a GFR <60 ml min -1 1.73 m -2 were not considered for this therapy.
Although weight-based dosing was suitable for this population, its use may result in high carboplatin exposures for patients with severe to moderate renal impairment. The use of a therapeutic drug monitoring approach is recommended in these patients, to monitor carboplatin concentrations closely. Similarly, no patients younger than 1.7 years were included in the study, and application of the weight-based dosing formula would need further validation in that population. In addition, further validation against independent carboplatin datasets would be desirable for verification of the reliability of weight-based dosing. Different assays were used at the two study sites, which could have influenced the analysis. To account for the assay differences between the sites, different residual error models were used, which significantly improved the model, with no observed bias in the parameter estimates.
Our study population consisted only of children aged 2-8 years. A previous study investigated the suitability of weight-based dosing for children up to 10 years [29] , suggesting that 50 mg kg -1 dosing may be useful for children up to 10 years of age. However, further studies are required to investigate whether 50 mg kg -1 dosing is suitable for older children and adolescents to achieve the target AUC of 16.4 mg ml -1 ·min.
There are two studies that have reported no pharmacokinetic interaction between carboplatin and etoposide [33, 34] , and one study has reported an interaction between melphalan and carboplatin [35] . As these drugs were coadministered in all patients in the present study, potential drug-drug interactions could not be investigated directly. A model-based evaluation of potential drug-drug interaction might be possible, but the magnitude of the previously reported effects was small.
The level of protein binding was not investigated in the present study. Etoposide is highly protein bound (90-95%) and melphalan has a moderate to high level of protein binding (60-90%, [36, 37] ). The unbound concentration of etoposide in the plasma is more closely associated with the pharmacodynamics and toxicity of etoposide than the bound drug [21] .
Conclusions
We investigated the pharmacokinetics of CEM in children and the utility of various dosing formulas for carboplatin dosing in a paediatric setting. Despite the use of GFR-based dosing protocols for carboplatin, our dosing simulations indicated that carboplatin doses of 50 mg kg -1 achieved the most consistent AUC relative to target exposure for children with mild renal impairment or normal renal function.
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